Gilead Sciences Inc (MIL:1GILD)
€ 82.27 -0.94 (-1.13%) Market Cap: 103.30 Bil Enterprise Value: 122.22 Bil PE Ratio: 109.56 PB Ratio: 6.12 GF Score: 76/100

Gilead Sciences Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 16, 2023 / 03:00PM GMT
Release Date Price: €73.08 (+1.11%)
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

Good morning. I'm Brian Abrahams, one of the senior biotech analysts here at RBC Capital Markets, and welcome again. Our next presenting company is Gilead. Really pleased to have with us their Chief Medical Officer, Merdad Parsey. Merdad, thank you again.

Merdad V. Parsey
Gilead Sciences, Inc. - Chief Medical Officer

Thanks. Thanks for having me.

Questions & Answers

Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

So a lot to cover. So I want to kick it off. Maybe starting with the oncology portfolio and Trodelvy. You recently got approval for Trodelvy based on the TROPiCS -- the positive TROPiCS-02 data. And I guess I was wondering if you could tell us a little bit more about what you're seeing since the approval in terms of how Trodelvy is being incorporated into clinical practice, maybe both what you're seeing in terms of the more mature triple-negative area as well as

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot